A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people
about
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVMultiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan childrenPoor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland - Data from Test and Keep in Care (TAK) ProjectHousing status and the health of people living with HIV/AIDSSwitching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice.Single-Tablet Regimens in HIV TherapySocial support as a predictor of early diagnosis, linkage, retention, and adherence to HIV care: results from the steps study.Global response to HIV: treatment as prevention, or treatment for treatment?Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United StatesLower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.Randomized clinical trial of HIV treatment adherence counseling interventions for people living with HIV and limited health literacyTreatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Comparison of HIV outcomes for patients linked at hospital versus community-based clinicsThe clinical role and cost-effectiveness of long-acting antiretroviral therapyRetention in care and medication adherence: current challenges to antiretroviral therapy success.The HIV Care Continuum: Changes over Time in Retention in Care and Viral SuppressionTwice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy.HIV treatment and care among Italian inmates: a one-month point survey.Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Health Outcomes of HIV-Infected People with Mental Illness.Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users.Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settingsMeta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment RegimensEffectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review.Diffusion of Newer HIV Prevention Innovations: Variable Practices of Frontline Infectious Diseases Physicians.Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV.Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen.Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatmentImpact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patientsSocio-economic- and sex-related disparities in rates of hospital admission among patients with HIV infection in Ontario: a population-based study.Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trialAssociation between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIVManaged problem solving for antiretroviral therapy adherence: a randomized trial.Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.
P2860
Q26799712-688092B5-4AAF-4F86-B3C1-B0D7E97C4076Q28483617-2572BE56-8068-4A79-B1AF-AE740AF77543Q28597880-ED99F689-0F6A-487C-8AD3-B6D7B19EB404Q30421169-78242474-7BDD-4735-B4FA-27A8A42F9B9AQ30795793-5878A3F4-26D5-4F00-B987-04C964EFF4CBQ33621206-8693E0B7-461E-4F4A-809B-CE33256D928CQ33939110-F223AB1A-E087-4688-A8E9-A6BADF30E03EQ34017310-473DC7F1-984C-4181-AD57-2848311CB9CEQ34077723-8A33DE45-3CFB-438F-8D7C-77BAA211D263Q34181784-5E5BEB3D-99B4-4AC7-8CD3-EF536449A4C3Q34464437-BF18B57F-F7DB-4C5A-9AD0-ACEAC8933CF3Q34788713-E1E6BFCC-B7A7-4F7D-BF13-F3F836B1674BQ35147189-A45B938D-81A7-43F8-B4D8-39EB5978B834Q35156672-243CC4EF-C67F-4671-9DCF-603D01FBB2A2Q35197271-5FEB9EE3-9CD1-4F02-90F5-3B372B88DAF8Q35257824-B458DAD4-92C9-416E-8D88-453FC720646BQ35666922-15CB3142-7DA0-4C44-8883-BDAF01B8267FQ35674849-B57D901B-756B-428F-B28A-5C8F25238880Q35808100-0321915E-77C6-4F92-B550-F38CB7D773BAQ35865208-90A93E2D-04B5-4885-BEA9-839D3B916D98Q35898538-CAB19411-A87F-4F0D-819E-9EC9C288C6CBQ35925058-D28BD9C1-293A-49EC-ADF1-5FD542DFF5F2Q36005097-B1082CE9-59FA-4C78-9A3C-F6195C48DB7BQ36031230-6439DF34-57AF-45E0-A7D4-7BD850DB779CQ36206941-17134D73-491D-47B0-B745-C387EC3DAD37Q36267762-D2BE7439-0991-486B-9EE6-6FB47A488271Q36292161-D8B1B148-35D3-4EED-ADA7-38C6B9F32114Q36346957-82EED7F3-45F8-4498-8FDC-480EAC4D297AQ36369137-D12CA41D-B0FF-4460-95B0-5C9819099641Q36463574-B825248B-FD1F-4393-8EBC-39BE5939DA35Q36617684-CA020782-6F87-48AE-9EFA-329F5B723EFBQ36715193-3075BE85-234B-4E75-B6C7-B089992508E4Q36795898-81415482-2B89-499C-BB7D-493647484D6BQ36813121-FF4AA3A6-31A9-419B-90F3-28E8A650823CQ36845581-E00D2F8E-C081-490A-81F0-DCA99505C047Q36875336-9AAECCA8-5CE9-4B05-9EAA-4671311D4E89Q36882476-028C9CC0-3FE8-402B-BFA0-D5788CCF5AB3Q37069682-B074F852-1C29-4AE9-A182-B451B4632872Q37317759-E66162B5-0E2D-4487-BF83-D86A921FDAD4Q37501229-2C9EB97F-ABB3-4088-A7CA-30CF54ED663B
P2860
A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A single tablet regimen is ass ...... s and marginally housed people
@ast
A single tablet regimen is ass ...... s and marginally housed people
@en
type
label
A single tablet regimen is ass ...... s and marginally housed people
@ast
A single tablet regimen is ass ...... s and marginally housed people
@en
prefLabel
A single tablet regimen is ass ...... s and marginally housed people
@ast
A single tablet regimen is ass ...... s and marginally housed people
@en
P2860
P1433
P1476
A single tablet regimen is ass ...... s and marginally housed people
@en
P2093
Kathleen Ragland
P2860
P304
P356
10.1097/QAD.0B013E328340A209
P407
P577
2010-11-01T00:00:00Z